Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Merck
Harvard Business School
McKinsey
Dow

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR FIRAZYR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Firazyr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00912093 ↗ A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed Shire Phase 3 2009-07-16 This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
NCT00997204 ↗ EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed Jerini AG Phase 3 2009-09-25 This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
NCT00997204 ↗ EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed Shire Phase 3 2009-09-25 This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
NCT01386658 ↗ A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Completed Shire Phase 3 2012-01-27 HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with Hereditary Angioedema (HAE) during an initial acute attack.
NCT01457430 ↗ Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed Shire Human Genetic Therapies, Inc. Phase 4 2011-12-01 The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.
NCT01457430 ↗ Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed Massachusetts General Hospital Phase 4 2011-12-01 The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Firazyr

Condition Name

Condition Name for Firazyr
Intervention Trials
Hereditary Angioedema 3
Hereditary Angioedema (HAE) 2
COVID-19 Pneumonia 1
ACE Inhibitor-associated Angioedema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Firazyr
Intervention Trials
Angioedema 7
Angioedemas, Hereditary 5
COVID-19 2
Pneumonia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Firazyr

Trials by Country

Trials by Country for Firazyr
Location Trials
United States 76
Canada 6
Australia 6
France 5
Israel 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Firazyr
Location Trials
California 7
Pennsylvania 5
Texas 4
Maryland 4
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Firazyr

Clinical Trial Phase

Clinical Trial Phase for Firazyr
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Firazyr
Clinical Trial Phase Trials
Completed 6
Recruiting 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Firazyr

Sponsor Name

Sponsor Name for Firazyr
Sponsor Trials
Shire 6
Jerini AG 1
Long Beach Memorial Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Firazyr
Sponsor Trials
Other 26
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Medtronic
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.